Literature DB >> 22542080

Signs and symptoms of parotid gland carcinoma and their prognostic value.

D Stodulski1, B Mikaszewski, C Stankiewicz.   

Abstract

The aim of this study was to analyse signs and symptoms present in patients with parotid gland carcinoma and to assess their prognostic value. A retrospective study of data from 131 patients who were treated surgically was performed. Evaluation of prognostic factors was possible in 109 patients who completed a minimum 5 year follow up. The most common sign and symptoms were parotid mass (96.9%), pain (40.4%), enlarged cervical lymph nodes (32.0%), facial nerve palsy (20.6%) and overlying skin infiltration (19.8%). In 20% of all cases there were no symptoms of tumour malignancy. The average duration of symptoms suggesting malignancy was 4 months. In univariate analysis, the strongest prognostic value was found for facial nerve palsy; it reduced nearly tenfold (9.7) the 5-year disease-free survival. The subsequent poor prognostic factors were: skin infiltration, enlarged cervical lymph nodes, tumour fixation and tumour size (>4 cm). Pain and the dynamics of tumour growth were not statistically significant for survival rate. Significant difference in 5-year disease free survival rate was found between the groups of patients, according to the number of symptoms suggesting malignancy. The multivariate analysis showed that only facial nerve palsy and skin infiltration were independent prognostic factors.
Copyright © 2012 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22542080     DOI: 10.1016/j.ijom.2011.12.020

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  8 in total

1.  Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies.

Authors:  Lorenz Kadletz; Klaus Aumayr; Gregor Heiduschka; Sven Schneider; Elisabeth Enzenhofer; Claudia Lill
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-07-28       Impact factor: 2.503

2.  BDNF/TRKB axis provokes EMT progression to induce cell aggressiveness via crosstalk with cancer-associated fibroblasts in human parotid gland cancer.

Authors:  Kazumasa Moriwaki; Masaki Wada; Hiroko Kuwabara; Yusuke Ayani; Tetsuya Terada; Masaaki Higashino; Ryo Kawata; Michio Asahi
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

3.  Primary parotid carcinoma: analysis of risk factors and validation of a prognostic index.

Authors:  Alberto Paderno; Michele Tomasoni; Davide Mattavelli; Simonetta Battocchio; Davide Lombardi; Piero Nicolai
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-09-12       Impact factor: 2.503

4.  Effect of clinical symptoms on the indication for selective neck dissection for N0 carcinomas of the parotid gland.

Authors:  Takashi Maruo; Yasushi Fujimoto; Kenji Yoshida; Mariko Hiramatsu; Atsushi Suzuki; Naoki Nishio; Mariko Shimono; Tsutomu Nakashima
Journal:  Oncol Lett       Date:  2014-05-12       Impact factor: 2.967

5.  Metastatic Malignant Melanoma of Parotid Gland with a Regressed Primary Tumor.

Authors:  M Mustafa Kılıçkaya; Giray Aynali; Ali Murat Ceyhan; Metin Çiriş
Journal:  Case Rep Otolaryngol       Date:  2016-07-05

6.  A clinicopathological study of parotid carcinoma: 18-year review of 171 patients at a single institution.

Authors:  Akira Nishikado; Ryo Kawata; Shin-Ichi Haginomori; Tetsuya Terada; Masaaki Higashino; Yoshitaka Kurisu; Yoshinobu Hirose
Journal:  Int J Clin Oncol       Date:  2018-03-21       Impact factor: 3.402

7.  Garcin syndrome caused by parotid gland adenoid cystic carcinoma: A case report.

Authors:  Nian-Ge Xia; Yan-Yan Chen; Xin-Shi Wang; Hui-Qin Xu; Rong-Yuan Zheng
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

8.  Clinicopathologic factors associated with recurrence in parotid carcinoma.

Authors:  Dong Hoon Lee; Tae Mi Yoon; Joon Kyoo Lee; Sang Chul Lim
Journal:  Braz J Otorhinolaryngol       Date:  2017-08-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.